Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Preferred Stock Liabilities (2019 - 2021)

Lyell Immunopharma (LYEL) has disclosed Preferred Stock Liabilities for 3 consecutive years, with $1.0 billion as the latest value for Q1 2021.

  • Quarterly Preferred Stock Liabilities changed N/A to $1.0 billion in Q1 2021 from the year-ago period, while the trailing twelve-month figure was $1.0 billion through Mar 2021, changed N/A year-over-year, with the annual reading at $1.0 billion for FY2020, 94.73% up from the prior year.
  • Preferred Stock Liabilities hit $1.0 billion in Q1 2021 for Lyell Immunopharma, roughly flat from $1.0 billion in the prior quarter.
  • In the past five years, Preferred Stock Liabilities ranged from a high of $1.0 billion in Q2 2020 to a low of $519.2 million in Q4 2019.
  • Historically, Preferred Stock Liabilities has averaged $912.6 million across 3 years, with a median of $1.0 billion in 2020.
  • Biggest YoY gain for Preferred Stock Liabilities was 94.73% in 2020; the steepest drop was 94.73% in 2020.
  • Year by year, Preferred Stock Liabilities stood at $519.2 million in 2019, then soared by 94.73% to $1.0 billion in 2020, then changed by 0.0% to $1.0 billion in 2021.
  • Business Quant data shows Preferred Stock Liabilities for LYEL at $1.0 billion in Q1 2021, $1.0 billion in Q4 2020, and $1.0 billion in Q3 2020.